Milan, 29 January 2026 – CIR S.p.A. (“CIR”) announces that today it has completed the acquisition of the 40.23% stake in the share capital of KOS S.p.A. held by F2i Healthcare S.p.A., pursuant to the binding agreement signed on 19 November 2025. The acquisition was carried out by CIR Investimenti S.p.A, a company wholly owned by CIR S.p.A..
Completion of the transaction followed the receipt of the required regulatory approvals, including those under Italian Golden Power and Italian antitrust regulations, as well as German antitrust rules, and the satisfaction of all the conditions precedent.
The purchase price for the shares amounts to €220.0 million. In accordance with the terms of the agreement, prior to closing KOS distributed an extraordinary reserve totaling €24.86 million.
The earn-out mechanisms and the anti-embarrassment clause remain applicable, in accordance with the terms already disclosed on 19 November 2025.
The transaction was financed by CIR using part of its available liquidity.
Following completion of the transaction, CIR holds, directly or indirectly, 100% of the share capital of KOS S.p.A.
